Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Heart failure is a major medical and socioeconomic problem in western industrial countries,
especially with aging populations. Heart failure with normal left ventricle systolic function
(heart failure with preserved ejection fraction, HFPEF, heart failure with normal ejection
fraction, HFNEF) are common causes of hospitalization mainly in the elderly population and
are frequently associated with pulmonary hypertension. It is commonly seen, that patients
with left heart disease and pulmonary hypertension with right ventricle dysfunction have a
worse prognosis.
The investigators hypothesize, that an additional treatment with Bosentan in this patients
will improve their exercise capacity, symptoms, hemodynamics and quality of life.